Catégorie : News_Corporate
-
Advanced BioDesign, winner of the France 2030 plan’s call for « i-DEMO » projects to finance its « Odyssey » clinical trial with up to €3M
Advanced BioDesign’s winning project is its first-in-human clinical trial of its drug candidate ABD-3001 for patients with acute myeloid leukaemia (AML) who are resistant to standard treatments.As part of the France 2030 plan, the « i-Demo » scheme supports the development of highly innovative, high added-value products and services to strengthen France’s scientific and technological capabilities. Lyon,…
Advanced BioDesign 